Ultra-Safe Hormonal Strategy: Transdermal Estradiol Added to Progestins for Endometriosis (TAEDIUMVITAE)

Transdermally Applied Estradiol Delivery In Ultra-Safe Medications Valuable In Treatment Against Endometriosis

Endometriosis is a chronic, estrogen-dependent disease affecting women of reproductive age, associated with pelvic pain, infertility, and reduced quality of life. Progestins are the standard first-line therapy, but long-term treatment requires well-tolerated regimens that balance efficacy with patient satisfaction.

This study will compare two combinations of progestins with natural transdermal estradiol-dienogest versus drospirenone-to evaluate which regimen provides greater patient satisfaction after 6 months of therapy.

Study Overview

• Status: Active, not recruiting
• Conditions: Endometriosis
• Intervention / Treatment: Drug: Drospirenone 4 mg orally; Drug: Dienogest 2 mg orally

Detailed Description

Endometriosis is a chronic, estrogen-dependent disorder characterized by the presence of endometrial tissue outside the uterine cavity. This ectopic tissue induces chronic inflammation, fibrosis, and adhesions, often resulting in pelvic pain, dysmenorrhea, dyspareunia, infertility, and impaired quality of life. The condition affects an estimated 6-10% of women of reproductive age, with peak prevalence between 25 and 35 years, making it one of the most common gynecological diseases with significant social and economic impact.

Available treatments for endometriosis are symptomatic rather than curative. Medical management is considered the cornerstone of therapy, especially in women who are not seeking immediate pregnancy. Current guidelines recommend progestins as first-line treatment due to their proven efficacy in suppressing endometriosis-associated pain and their favorable safety and tolerability profile. However, because therapy is usually long-term until menopause and continuous, optimal regimens must combine efficacy with good tolerability and sustained patient satisfaction.

Dienogest is an established fourth-generation progestin widely used in endometriosis management, with well-documented efficacy and safety. Drospirenone, another fourth-generation progestin, combines progestogenic, anti-androgenic, and anti-mineralocorticoid activities. Although marketed primarily as a contraceptive, drospirenone has shown promising results in controlling endometriosis symptoms and improving patient-reported outcomes.

Progestin-only regimens may lead to hypoestrogenic adverse effects, including vaginal dryness, mood disturbances, reduced libido, irregular bleeding, and bone loss. For this reason, the addition of natural estradiol is considered advantageous, as it may prevent atrophic changes, support bone metabolism, and improve overall quality of life. Transdermal estradiol, in particular, avoids hepatic first-pass metabolism, does not induce prothrombotic liver factors, and is associated with a lower risk of thromboembolic events compared with ethinyl estradiol.

This observational study is designed to directly compare two therapeutic strategies for women with endometriosis: Dienogest + transdermal estradiol or Drospirenone + transdermal estradiol.

The primary endpoint is patient satisfaction after 6 months of treatment, reflecting the central importance of patient-centered outcomes in a chronic disease that impacts multiple aspects of daily life. Secondary endpoints include sexual function, psychological well-being, and health-related quality of life, assessed with validated questionnaires.

By comparing two modern progestin-based regimens combined with natural estradiol, this study aims to generate evidence that will help clinicians tailor hormonal therapy to improve not only symptom control but also the long-term well-being and quality of life of women with endometriosis.

• Study Type: Observational
• Enrollment (Estimated): 138

Contacts and Locations

Study Locations

• Italy
  • Milan, Italy, 20122
    • Gynecology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Women with endometriosis referred to the endometriosis outpatient clinic of the Gynaecology SC of the Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico in Milan between October 2024 and September 2025 will be included in the study. The diagnosis of endometriosis is made on the basis of the combination of symptomatology + gynaecological examination, transvaginal/transrectal ultrasound or previous surgical visualisation of the disease.

Description

Inclusion Criteria:

• women who have been on combination therapy for at least 6 months with progestin and transdermal natural oestrogen (Dienogest + transdermal oestradiol or Drospirenone + transdermal oestradiol);
• women who have performed follow-up at least 6 months after the start of treatment and for whom data on the primary endpoint of the study (treatment satisfaction) are available.

Exclusion Criteria:

• absence of surgical diagnosis or imaging indicative of endometriosis or adenomyosis;
• women who have taken GnRH analogue therapy within 6 months prior to treatment with dienogest + transdermal oestradiol vs. drospirenone + transdermal oestradiol
• women who have taken only progestogen therapy without transdermal oestradiol or with contraindications to oestrogen use;
• women who received surgical indications during the treatment period, including obstructive uropathy or symptomatic bowel stricture; evidence of complex ovarian cysts or ovarian endometriomas with a diameter greater than 5 cm on transvaginal ultrasound.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Women with endometriosis undergoing medical management; This cohort will include women of reproductive age with a confirmed diagnosis of endometriosis, either by laparoscopy/histology or by validated imaging techniques (e.g., transvaginal ultrasound, MRI).	Drug: Drospirenone 4 mg orally; Daily oral administration of Drospirenone 4 mg + Transdermal estradiol; continuous administration for at least 6 months.; Other Names: Slinda; Drug: Dienogest 2 mg orally; Daily oral administration of Dienogest 2 mg + Transdermal estradiol; continuous administration for at least 6 months.; Other Names: Visanne; Dienogest; Zafrilla

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patients' statisfaction	Therapy satisfaction will be assessed by means of a 5-level Likert scale (very satisfied; satisfied; neither satisfied nor dissatisfied; dissatisfied; very dissatisfied). Women expressing the judgement 'very satisfied' and 'satisfied' will be considered to be globally satisfied, similarly to reported in the study on which the calculation of the sample size is based. The outcome will be dichotomised (very satisfied + satisfied versus neither satisfied nor dissatisfied + dissatisfied + very dissatisfied). The level of statisfaction in the two groups will be compared as the proportion of satisfied women in each treatment group, reported as frequencies and percentages and analyzed accordingly.	This outcome will be evaluated after at least 6 months of treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Therapeutic efficacy - symptoms control (NRS)	Symptoms control, measured by Numeric Rating Scale (NRS), 11-point (0 = no pain; 10 = worst imaginable pain) for the following symptoms: dysmenorrhea, deep dyspareunia, superficial dyspareunia, non-menstrual pelvic pain, pain during defecation, pain during urination.	This outcome will be evaluated after at least 6 months of treatment
Therapeutic efficacy - symptoms control (use of analgesics)	Symptoms control, measured by use of analgesic therapy for pain symptoms, as reported during clinical evaluation (0 = no, 1 = yes).	This outcome will be evaluated after at least 6 months of treatment
Therapeutic efficacy - ovulation suppression	Confirmation of ovulation suppression, the therapeutic goal in endometriosis management, through serum measurement of 17β-estradiol, progesterone, and follicle-stimulating hormone (FSH), according to clinical practice.	This outcome will be evaluated after at least 6 months of treatment
Therapeutic efficacy - amenorrhea achievement and bleeding pattern	Bleeding pattern during treatment, with number achieving amenorrhea (therapeutic goal in endometriosis medical management). Unexpected uterine bleeding will be recorded as: spotting, menstrual-like bleeding, or heavy bleeding. The cumulative number of bleeding days and the number of treatment interruptions lasting one week (tailored cycling) to manage irregular bleeding will be collected.	This outcome will be evaluated after at least 6 months of treatment
Global Impression of Change	Patients' Global Impression of Change (PGIC) Scale, single-item, 7-point Likert scale (very much improved; much improved; minimally improved; no change; minimally worse; worse; very much worse).	This outcome will be evaluated after at least 6 months of treatment
Sexual function	Measured by the Female Sexual Function Index (FSFI), 19-item questionnaire with 5-point Likert scale. The final score will be interpreted as continuous (lower scores indicating worse sexual function)	This outcome will be evaluated after at least 6 months of treatment
Mood changes	Measured by the Hospital Anxiety and Depression Scale (HADS), 14-item, 4-point Likert scale. The total score will be interpreted as continuous (lower scores indicating better psychological status).	This outcome will be evaluated after at least 6 months of treatment
Health-related quality of life (HRQoL)	Calculated using the 12-Item Short Form Health Survey (SF-12) questionnaire, with Physical Component Summary (PCS-12) and Mental Component Summary (MCS-12). The total score will be interpreted as continuous (lower scores indicating worse health status).	This outcome will be evaluated after at least 6 months of treatment
Acceptance of transdermal therapy	Measured by: 11-point numeric scale (0 = no discomfort; 10 = worst imaginable discomfort).; 5-level categorical scale (1 = no discomfort; 5 = intolerable discomfort).	This outcome will be evaluated after at least 6 months of treatment
Adverse events	Assessed globally through a single-item question on side effects reported during treatment (as previously used in the sample size reference study). Reported side effects will be collected, and, if present, their impact on quality of life will be evaluated using a 10-point numeric scale (1 = minimal impact; 10 = maximum impact).	This outcome will be evaluated after at least 6 months of treatment
Treatment adherence	Measured by the Morisky Medication-Taking Adherence Scale (MMAS-4), single-item, with scores ranging from 0 = excellent adherence to 4 = poor adherence.	This outcome will be evaluated after at least 6 months of treatment

Collaborators and Investigators

• Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Study record dates

Study Major Dates

• Study Start (Actual): August 11, 2025
• Primary Completion (Estimated): February 1, 2026
• Study Completion (Estimated): February 1, 2026

Study Registration Dates

• First Submitted: September 8, 2025
• First Submitted That Met QC Criteria: September 24, 2025
• First Posted (Estimated): October 2, 2025

Study Record Updates

• Last Update Posted (Estimated): October 2, 2025
• Last Update Submitted That Met QC Criteria: September 24, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Genital Diseases, Female; Endometriosis; dienogest; drospirenone
• Other Study ID Numbers: 0021423-U; TAEDIUMVITAE (Other Identifier: Comitato Etico Territoriale Lombardia 3)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No